Overall, despite the importance of the PI3K pathway in breast cancer and therapy resistance, many PI3K inhibitors used as monotherapy reported limited efficacy and high toxicity profile in current clinical trials across breast cancer subtypes. Here, PIK3CB is linked to breast cancer.